ProCE Banner Activity

Venetoclax in Patients With CLL Relapsed/Refractory to Ibrutinib or Idelalisib

Slideset Download
Conference Coverage
Venetoclax associated with high response rates and durable responses in patients with CLL who progressed on ibrutinib, idelalisib, or both.

Released: December 08, 2016

Expiration: December 07, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Seagen